COVID-19
COVID-19 treatments: under evaluation
The European Medicines Agency (EMA) is evaluating potential COVID-19 treatments to enable promising medicines to reach patients in the European Union (EU) as soon as possible.
EMA’s CHMP is evaluating the following COVID-19 treatments:
| Treatment | Treatment developer | Key milestones | More information |
|---|---|---|---|
| REGN-COV2 antibody combination (casirivimab / imdevimab) | Regeneron Pharmaceuticals, Inc. and F. Hoffman-La Roche, Ltd (Roche) |
Start of rolling review: 01/02/2021
|
|
| Monoclonal antibody regdanvimab | Celltrion | Start of rolling review: 24/02/2021 | EMA starts rolling review of Celltrion antibody regdanvimab for COVID-19 |
| Monoclonal antibodies bamlanivimab and etesevimab | Eli Lilly | Start of rolling review: 11/03/2021 | EMA starts rolling review of Eli Lilly antibodies bamlanivimab and etesevimab for COVID-19 |